BioNexus Gene Lab (BGLC) Shares Outstanding (Diluted Average) (2023 - 2026)

BioNexus Gene Lab has disclosed Shares Outstanding (Diluted Average) across 4 years of filings, most recently posting $2.4 million for Q1 2026.

• Shares Outstanding (Diluted Average) for Q1 2026 came in at $2.4 million, up 34.54% year-over-year; the trailing twelve-month figure through Mar 2026 was $2.4 million (up 34.54% YoY), and the FY2024 annual result was $17.8 million, up 12.24% from the prior year.
• Shares Outstanding (Diluted Average) came in at $2.4 million for Q1 2026 at BioNexus Gene Lab, up from $1.8 million in the prior quarter.
• In the past five years, Shares Outstanding (Diluted Average) ranged from a high of $17.8 million in Q4 2024 to a low of $1.8 million in Q2 2024.
• The 4-year median for Shares Outstanding (Diluted Average) is $1.8 million (2025), against an average of $7.0 million.
• Across the five-year window, Shares Outstanding (Diluted Average) slumped 89.83% in 2025 and jumped 34.54% in 2026, its largest moves.
• BioNexus Gene Lab's Shares Outstanding (Diluted Average) stood at $15.9 million in 2023, then grew by 12.24% to $17.8 million in 2024, then tumbled by 89.92% to $1.8 million in 2025, then soared by 34.55% to $2.4 million in 2026.
• The last three Shares Outstanding (Diluted Average) figures came in at $2.4 million (Q1 2026), $1.8 million (Q3 2025), and $1.8 million (Q2 2025), per Business Quant data.